Longevity, Interpreted.
A scientist’s reading of the evidence
Most longevity claims travel further than their evidence. Each week I read the primary literature, the trial registries and the regulators, and report how far: what was shown, at what stage, and what it does not yet support.
Get this weekly, freeFree · Saturday and Sunday · one click to leave
- Every claim carries its stage of evidence, from a mouse study to a randomised human outcome trial.
- When new work changes nothing, the issue says so, and why. That is most weeks.
- Nothing to sell you. No clinic, no supplement line, no intervention I am paid to defend.
- Global signal, read with an India lens.
The latest issue · 31 August – 6 September 2026
Business
- GLP-1 agonists now have a rodent lifespan result
- A paid layer is forming around GLP-1 prescriptions
- Clock supply is outrunning clock proof
Healthspan
- Muscle add-ons for weight-loss drugs entered testing before the problem was settled
- Semaglutide extended lifespan in mice dosed in old age
- A rapamycin-class drug enters a human aging trial that measures markers
- Four more ways to estimate your biological age, none with a demonstrated use
Every issue
- 31 August – 6 September 2026Business · Healthspan
Edited by
Sucheendra Kumar Palaniappan
Scientist working at the intersection of computation, biology and medicine. Longevity, Interpreted. exists to understand the evidence, not sell an intervention.
All issues · Subscribe · suchee.org · LinkedIn · Scholar
Mice are not humans · Biomarkers are not outcomes
· Funding is not validation